Abstract
BACKGROUND: Owing to adverse pharmacokinetics, azathioprine treatment may fail to induce a satisfactory clinical response in systemic connective tissue diseases. The major intracellular cytotoxic metabolites of azathioprine are 6-thioguanine nucleotides (6TGNs). METHODS: To assess whether the erythrocyte accumulation of 6TGN is a clinically applicable index for monitoring azathioprine treatment, erythrocyte accumulation of 6TGN was measured in patients with rheumatoid arthritis (n = 12), systemic lupus erythematosus (n = 7), polyarteritis nodosa (n = 2), myositis (n = 1), or leukocytoclastic vasculitis (n = 1). Ages ranged from 28 to 75 (median 58) years. RESULTS: Erythrocyte accumulation of 6TGN varied among the patients from 20 to 303 (median value 95) nmol/mmol haemoglobin. No significant correlation was found between erythrocyte accumulation of 6TGN and the dose of azathioprine/kg body weight, the age of the patients, the duration of treatment, or the presence of myelotoxicity or hepatotoxicity. The interindividual coefficient of variation (CV) in the erythrocyte accumulation of 6TGN/mg azathioprine/kg body weight was 0.65. The median intraindividual CV in erythrocyte accumulation of 6TGN at an unchanged dose of azathioprine was 0.09 (19 patients; range 0.03-0.27). CONCLUSIONS: The low intraindividual variation compared with the high interpatient variation in erythrocyte accumulation of 6TGN implies that erythrocyte accumulation of 6TGN may be clinically applicable for monitoring azathioprine treatment. Prospective studies are needed to clarify the relation between the erythrocyte accumulation of 6TGN and the clinical response to treatment, and to establish recommendations for dose modifications.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bruunshuus I., Schmiegelow K. Analysis of 6-mercaptopurine, 6-thioguanine nucleotides, and 6-thiouric acid in biological fluids by high-performance liquid chromatography. Scand J Clin Lab Invest. 1989 Dec;49(8):779–784. doi: 10.3109/00365518909091557. [DOI] [PubMed] [Google Scholar]
- Chan G. L., Erdmann G. R., Gruber S. A., Stock P., Chen S., Ascher N. L., Canafax D. M. Pharmacokinetics of 6-thiouric acid and 6-mercaptopurine in renal allograft recipients after oral administration of azathioprine. Eur J Clin Pharmacol. 1989;36(3):265–271. doi: 10.1007/BF00558158. [DOI] [PubMed] [Google Scholar]
- Lennard L., Brown C. B., Fox M., Maddocks J. L. Azathioprine metabolism in kidney transplant recipients. Br J Clin Pharmacol. 1984 Nov;18(5):693–700. doi: 10.1111/j.1365-2125.1984.tb02531.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lennard L., Lilleyman J. S., Van Loon J., Weinshilboum R. M. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet. 1990 Jul 28;336(8709):225–229. doi: 10.1016/0140-6736(90)91745-v. [DOI] [PubMed] [Google Scholar]
- Schmiegelow K., Bruunshuus I. 6-Thioguanine nucleotide accumulation in red blood cells during maintenance chemotherapy for childhood acute lymphoblastic leukemia, and its relation to leukopenia. Cancer Chemother Pharmacol. 1990;26(4):288–292. doi: 10.1007/BF02897232. [DOI] [PubMed] [Google Scholar]
- Sztejnbok M., Stewart A., Diamond H., Kaplan D. Azathioprine in the treatment of systemic lupus erythematosus. A controlled study. Arthritis Rheum. 1971 Sep-Oct;14(5):639–645. doi: 10.1002/art.1780140511. [DOI] [PubMed] [Google Scholar]
- Van Scoik K. G., Johnson C. A., Porter W. R. The pharmacology and metabolism of the thiopurine drugs 6-mercaptopurine and azathioprine. Drug Metab Rev. 1985;16(1-2):157–174. doi: 10.3109/03602538508991433. [DOI] [PubMed] [Google Scholar]
- Weinshilboum R. Pharmacogenetics of methylation: relationship to drug metabolism. Clin Biochem. 1988 Aug;21(4):201–210. doi: 10.1016/s0009-9120(88)80002-x. [DOI] [PubMed] [Google Scholar]